1. Scrip

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Analysts call FDA vaccine guidelines balanced, but with potential to cause Moderna problems

Market analysts have deemed the US Food and Drug Administration’s COVID-19 vaccine policy unveiled 20 May as far from a worst-case scenario for vaccine-focused firms – for example, approved vaccines will not be removed from the market – but the immediate stock price bounce companies like Pfizer, BioNTech, Moderna and Novavax got from the news dissipated during the 21 May trading day.

Key Takeaways
  • The FDA vaccine regulatory framework unveiled on 20 May fell short of a worst-case scenario, such as approved vaccines being removed from the market, analysts said.

In a 21 May note, William Blair analyst Myles Minter said the new FDA regulatory policy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.